ACADIA Pharmaceuticals Inc. Overview
Pro stress-test →ACADIA Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines addressing unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company projects 2028 combined net sales of approximately $1.7 billion, with ~$1 billion for NUPLAZID and ~$700 million for DAYBUE.
Strategic Profile
Pro stress-test →ACADIA operates two core franchises: its neuroscience franchise anchored by NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis, and its neuro-rare disease franchise anchored by DAYBUE (trofinetide) for Rett syndrome. The company is advancing its R&D pipeline with plans to initiate five Phase 2 or Phase 3 studies across eight disclosed programs and deliver four Phase 2 or Phase 3 readouts by the end of 2027.
Competitive Landscape
Pro stress-test →ACADIA's expanding product demand, strong pipeline progress, and strategic outreach broaden patient base and diversify revenue, while favorable regulatory trends and industry consolidation enable faster market access. The company competes in specialized CNS and rare disease markets with limited direct competitors in its specific indications, maintaining competitive advantages through proprietary mechanisms of action and clinical data.
Industry Context
ACADIA Pharmaceuticals Inc. operates in Biopharmaceuticals - CNS Disorders & Rare Diseases.
Key facts
Founded: 1993 · Headquarters: San Diego, US · Employees: N/A · Revenue: $1.05B · Market cap: $3.8B